Director Leo Chandra P. bought 10,000 (10.0K shares) of GLUE at $5.84; stock down 45.3% from 52-week high, company unprofitable with $-23.9M net income.
Leo Chandra P. established an initial 10,000-share position in Monte Rosa Therapeutics at $5.84 per share, representing his first purchase in the company. The transaction occurs in a deteriorated price environment: the stock trades 45.3% below its 52-week high of $10.36 and has declined 19.6% over the prior 90 days. Monte Rosa is unprofitable with reported net income of $-23.9M against quarterly revenue of $9.2M, indicating significant cash burn in its therapeutic development stage. As a director, Chandra's initial stake warrants attention to whether it signals foundational confidence in the platform or is a routine board-related acquisition, though the combination of losses and valuation decline from recent peaks creates a different context than a purchase near all-time highs.